

## SEROLOGICAL RESPONSE OF COMMERCIAL LAYING HENS TO *Mycoplasma gallisepticum* IN POULTRY FARMS IN SÃO PAULO STATE

(REAÇÕES SOROLÓGICAS CONTRA *Mycoplasma gallisepticum* EM AVES DE POSTURA DE GRANJAS COMERCIAIS NO ESTADO DE SÃO PAULO)

L. M. CORREZOLA<sup>1,2</sup>, F. G. BUCHALA<sup>2</sup>, S. M. M. VITAGLIANO<sup>2</sup>, R. S. JORDÃO<sup>3</sup>,  
M. R. BUIM<sup>3</sup>, C. DEL FAVA<sup>3\*</sup>

### SUMMARY

The seroreactivity of commercial laying hens for *Mycoplasma gallisepticum* was evaluated by plate seroagglutination test (SAR) and ELISA, a screening and confirmatory test, respectively. The trial run during June and July, 2009 in poultry farms located in the Bastos region and in the city of Guatapar, SP. The Bastos region total seroreactivity for SAR was 88.2% (566/642), from which 85.5% (196/229) non-vaccinated and 89.5% (370/413) vaccinated laying hens. Whereas total seroreactivity for ELISA was 89.8% (577/642), from which 97.40% (233/229) non vaccinated and 85.7% (354/413) vaccinated laying hens. In the municipality of Guatapar, all the flocks were vaccinated against *M. gallisepticum*, and seroreactivity rates were 76.5% (108/141) for SAR and 97.20% (137/141) for ELISA. In the region of Bastos, 84.30% (193/229) of the non- vaccinated hens were simultaneously reactive to SAR and ELISA; however, there was no clinical case of infection, and this high rate of seroreactivity may be due to the diffusion of live vaccine strain (ts-11 or F), which have low pathogenicity and immunize hens against wild strains. The high rate of vaccinated hens in both regions simultaneously reactive to SAR and ELISA, 84.00% (465/554) or the 8.80% (49/554) reactive to ELISA only, as well as the absence of clinical signs show low vaccine failure and its effectiveness in protecting the flocks against chronic respiratory disease.

**KEY-WORDS:** Chronic respiratory disease. Commercial laying hens. Mycoplasmosis. Sorodiagnosis.

### RESUMO

Avaliaram-se reaes sorolgicas contra *Mycoplasma gallisepticum* em aves de postura comercial no Bolso de Bastos e no Municpio de Guatapar, Estado de So Paulo, no perodo junho-julho/2009, utilizando a soroaglutinao rpida (SAR) como triagem e o ELISA como teste confirmatrio. No Bolso de Bastos, na SAR observou-se sororreatividade total de 88,2% (566/642), sendo para aves no vacinadas contra *M. gallisepticum* 85,5% (196/229) e vacinadas 89,5% (370/413), e pelo ELISA, reatividade total 89,8% (577/642), para aves no vacinadas 97,40% (233/229) e aves vacinadas 85,7% (354/413). Em Guatapar, todas as granjas amostradas utilizavam vacinao (cepa ts-11); a proporo de reagentes na SAR foi 76,5% (108/141) e no ELISA 97,20% (137/141). No Bolso de Bastos, onde as aves no vacinadas apresentaram elevadosndices de sororreatividade simultaneamente na SAR e no ELISA, 84,30% (193/229), no foram observados casos clnicos da infeco, fato que pode ser atribudo  difuso de cepas vacinais vivas (F ou ts-11), que possuem baixa patogenicidade e imunizam as aves contra as cepas de campo. O grande percentual de aves imunizadas, nas duas regies, que foram reagentes simultaneamente na SAR e no ELISA – 84,00% (465/554) ou reagentes somente ao ELISA – 8,80% (49/554) e a ausncia de sinais clnicos indica que houve pouca falha vacinal, com a vacina protegendo-as da doena crnica respiratria.

**PALAVRAS-CHAVE:** Aves de postura comercial. Doena crnica respiratria. Micoplasmose. Sorodiagnstico.

<sup>1</sup>Veterinarian at Associao Paulista de Avicultura and Master Student at *strictu sensu* Postgraduation course in Sanidade Animal, Segurana Alimentar e o Ambiente – Instituto Biolgico/SP.

<sup>2</sup>Veterinarians at Coordenadoria de Defesa Agropecuria do Estado de So Paulo, Campinas/SP.

<sup>3</sup>Scientific researchers at Instituto Biolgico/APTA – Av. Conselheiro Rodrigues Alves, 1252, Vila Mariana, CEP 04014-002. So Paulo/SP/Brasil. Telefax (11) 5087-1710. \* Corresponding author: [delfava@biologico.sp.gov.br](mailto:delfava@biologico.sp.gov.br)

## INTRODUCTION

*Mycoplasma gallisepticum* is a major problem for the poultry industry since it is associated with chronic respiratory disease (CRD) and can be transmitted vertically by the egg. The economical losses are due to declining egg production and quality (NOORMOHAMMADI et al., 2002), as well as low hatchability, high rate of culled chicks, poor feeding efficiency, high drug costs, bacterial resistance and trade restrictions (METTIFOGO & BUIM, 2009).

The Plano Nacional de Sanidade Avícola (PNSA, National Poultry Health) provides for the official monitoring of broiler breeder (parents, grandparents and genetic nucleus farms) for *M. gallisepticum*, *M. synoviae* and/or *M. meleagridis*, following epidemiological sampling procedures and frequency. The diagnostic screening and confirmatory tests are plate seroagglutination test (SAR) and haemagglutination inhibition (HI) or ELISA, respectively, as well as isolation and typifying and/or PCR. Additionally, broilers can be tested before and during slaughtering, as well commercial laying hens at farms (BRASIL, 1994).

Although *M. gallisepticum* is not officially controlled in laying hen farms, seroepidemiological studies were performed using SAR, in Brazil. In Rio de Janeiro, Danelli et al. (1999) found 17% (11/64) seropositive non-vaccinated poultry, Mendonça et al. (2003) reported 41.7%, and Simas et al. (2008), 94% (47/50). In Rio Grande do Sul, Rauber et al. (2004) reported for chicken farms, A - 26% (7/27), B - 56.6% (34/60) and C - 18.1% (27/149). In Minas Gerais, Santos et al. (2007) found 2% (6/300) seropositive non-vaccinated poultry.

The live vaccine is recommended for commercial laying hens to reduce production losses and to prevent transmission of infection (NASCIMENTO, 2000). The use of live vaccine against *M. gallisepticum* causes weak immune response, while high titers of antibodies in ELISA indicate that the vaccinated groups are facing the challenge in the field, and it is therefore, necessary to verify the presence of clinical signs (BUTCHER, 2009; MUÑOZ et al., 2009).

Giving the economic importance of commercial laying hens in two regions of São Paulo state: the Bastos region and the city of Guatapar, as well as the lack of data regarding the presence of *M. gallisepticum* in the poultry industry, this study evaluated the occurrence of serological reactions using SAR and ELISA, as screening and confirmatory tests, respectively, as well as bird humoral response to vaccination according to production stage and age.

## MATERIAL AND METHODS

Blood samples were collected from commercial laying hens in two regions of São Paulo, Bastos and Guatapar. The Bastos region is located in Nova Alta Paulista, latitude 21°55'19" S and longitude 50°44'02" W, at 445 m altitude and covers an area of 170.454

km<sup>2</sup>. This region has the largest flock of laying hens and is responsible for the largest egg production in Brazil (CDA, 2009). The Bastos region was created by Resolution SAA-27, on 30/09/2003, and includes 16 other counties besides Bastos, among them Iacri, Osvaldo Cruz and Tup. It accounts for 15% of the national flock of laying hens and produces more than 8.6 million eggs per day (SO PAULO, 2003). The chicken farms studied were selected from the database of the Sindicato Rural de Bastos, SP, according to the criterion whether the animals were vaccinated or not against mycoplasmosis.

The city of Guatapar is located in the Ribeiro Preto region, northeast of So Paulo, at latitude 21°29'48" S and longitude 48°02'16" W, covers an area of 412.637 km<sup>2</sup> (CDA, 2009). The main economic activity is egg production, averaging 21,000 dozen eggs per day, and ranks as the 18<sup>th</sup> Brazilian city in egg production according to the Instituto Brasileiro de Geografia e Estatstica (IBGE, 2009). The database of the Cooperativa Agrcola Mombuca was used to select the chicken farms in this county.

In the Bastos region, blood samples were collected in 10 chicken farms, four lots per farm, on average 16 birds per lot. The animals were classified according to age (weeks) and production stage, beginning, peak and end of egg production. In Guatapar, 160 blood samples were collected in each one of the 10 farms.

Blood samples were collected by venipuncture of the humeral vein, using a 3-mL disposable syringe and needle 21 x 0.7 mm. Every 3-mL blood sample was labeled according to lot and farm to which it belonged. The procedures were approved by the Ethics Committee for Animal Experimentation of the Instituto Biolgico (CETEA-IB), registered under protocol CETEA 77/09, approved on March 18, 2009.

After blood coagulation and serum separation, the SAR test was performed. An aliquot of each serum sample was individually stored in *Eppendorf* vials and frozen at -20°C to be used for ELISA.

The methodology used to perform SAR and ELISA is recommended by MAPA (Brasil, 1994). The SAR antigen used was Myco-Galli Teste®, BIOVET, consisting of a suspension of inactivated *M. gallisepticum* strain S-6. All vials belonged to the same 869/08 lot. The ELISA was performed using a kit to detect antibodies against *M. gallisepticum* Flock Chek Idexx®, following manufacturer guidelines. The ELISA cutoff to determine whether a sample was reagent or not, geometric mean titer (GMT) as well as the other statistical variables, coefficient of variance (CV), standard deviation (SD), maximum and minimum values were calculated by the software xCheck 3.3 (Idexx®).

Statistical differences between seroreactivity levels of SAR and ELISA for vaccinated and non-vaccinated animals, according to production stage (age) were calculated by Chi-square test, at 5%.

The GMT values of the ELISA test for *M. gallisepticum* in vaccinated birds, according to production stage and age, for both regions Bastos and Guatapar, SP, were compared by Tukey test, at 5%.

## RESULTS AND DISCUSSION

The Bastos region had a high rate of birds reactive to SAR and ELISA, respectively, 88.2% (566/642) and 89.8% (577/642). The vaccinated lots had 89.5% (370/413) seroreactivity to SAR, whereas among the non-vaccinated 97.4% (223/229) were reactive to ELISA. The birds were vaccinated with live strains F or ts-11, and seroreactivity of these lots varied from 50 to 100% for SAR and from 31.25 to 100% for ELISA. For non-vaccinated birds, seroreactivity varied from 0 to 100% for SAR and from 78.95 to 100% for ELISA.

In Guatapar where all the vaccinated chicken received the live strain ts-11, there was a high rate of birds reactive to SAR and ELISA, 76.5% (108/141) and 97.2% (137/141), respectively. The seroreactivity of each lot varied from 50 to 100% and from 80 to 100% for SAR and ELISA, respectively.

It was important to evaluate the response of both tests together, screening SAR and confirmatory ELISA, since SAR detects IgM and indicates seroconversion, while ELISA detects IgG and chronic infection (NASCIMENTO, 2000; BUTCHER, 2009).

In regions of intense poultry business, such as Bastos and Guatapar, where the vaccination uses live strains of low pathogenicity against mycoplasmosis, the vaccine agent is widely spread by aerosol among lots and even among farms, which may end up infecting non-vaccinated birds with the attenuated strain. In the Bastos region, 84.3% (193/229) of the non-vaccinated birds were seroreactive to SAR and ELISA simultaneously, which indicated that the majority was in the acute stage of infection; however, there were no birds with respiratory signs. These lots with non-vaccinated seroreactive birds were probably infected with the mild strain contracted from the vaccinated birds of the same farm or neighboring farms that was spread in the environment. These low pathogenic live vaccine strains F and ts-11 colonize the upper respiratory tract of birds and compete with pathogenic strains for a connection with the receptors on the tracheal epithelium (METTIFOGO & BUIM, 2009).

Considering the high number of vaccinated birds in these two regions, the humoral response of these two populations was also evaluated. A high number was reactive to both SAR and ELISA, 84% (465/554), showing that the birds had IgM and IgG antibodies or reactive to ELISA only, 8.8% (49/554), with IgG antibodies. These data indicated the humoral response expected in a population that is subjected to mass vaccination using live attenuated strain, where a large percentage of seroreactive birds can be found. Since no clinical respiratory symptoms were observed in the vaccinated birds, one can assume that spreading of the live attenuated strain protected the population against virulent field strains (METTIFOGO & BUIM, 2009). In addition, a low percentage of vaccinated birds were not reactive to both ELISA and SAR simultaneously, 3.6% (20/554), thus indicating low vaccine failure.

In both regions, mycoplasmosis control is accomplished primarily by vaccination and not

biosafety measures. The farms were densely populated and very close, with no physical barrier to separate them. It is also very common to have birds of multiple ages, at different reproduction stages in the same farm, which may have contributed to the spread of the strains and high total reactivity to SAR 86.1% (674/783) and ELISA 91.2% (714/783). Ito et al. (2002) emphasized that biosafety is the single most important preventive measure to avoid introduction of *M. gallisepticum* in chicken farms, and Nascimento (2000) points out that multiple lots of different ages in the same farm act as a facilitator for emergence of intercurrent diseases and the spread of pathogens among the birds of the same lot and among lots as well.

Regardless of the production system of commercial laying hens, the egg production phase lasts the same, it starts and finishes on the 17<sup>th</sup> and 72<sup>nd</sup> weeks, respectively (ALVES, 2006; GARCIA & MOLINA, 2008). In order to evaluate the impact of the production stage on the seroreactivity of the vaccinated lots, the laying period was divided into early (17-35 weeks), middle (36-53 weeks) and final (from the 54<sup>th</sup> week on). The Chi-squared test showed a statistically significant effect of age on the seroreactivity to *M. gallisepticum*; fewer birds aged  $\geq 54$  had IgM antibodies detected by SAR ( $P = 0.0499$ ) and more birds had IgG antibodies by ELISA ( $P = 0.0162$ ) (Table 1), thus showing the chronicity of infection or vaccination (METTIFOGO & BUIM, 2009).

There was a statistically significant effect of age on the seroreactivity to *M. gallisepticum* of non-vaccinated birds; more birds aged  $\geq 54$  weeks had IgM antibodies ( $P < 0.001$ ), indicating recent infection and also chronicity by IgG ( $P < 0.001$ ) (Table 2); however, since there were no birds with clinical respiratory symptoms, one concludes that the vaccine strain of low virulence spread stimulating the immune system (METTIFOGO & BUIM, 2009).

The geometric mean titer (GMT) of ELISA for vaccinated bird varied widely within the same lot and farm, in both regions, also standard deviation (SD), coefficient of variance (CV) and minimum and maximum values were high. The comparison of GMT values of ELISA of vaccinated lots by Tukey test at 5% showed no statistical difference regarding production phase and age ( $P > 0.05$ ) (Table 3). Taking into consideration that laying hens are vaccinated young, the serological reactions after live vaccine did not result in high titers of ELISA, the presence of high titers indicate field challenge, however, as there were no clinical signs of CRD, one can hypothesize that his humoral immune response is due to infection by attenuated vaccine strain or low virulence field (BUTCHER, 2009; MUÑOZ et al., 2009).

Since vaccination against *M. gallisepticum* is widely spread in commercial laying birds, it was difficult to find non-vaccinated animals and therefore, it was not possible to apply Tukey test to compare GMT of different ages in the Bastos region.

SAR is a screening test with low specificity, which is why false-positive results may occur. This fact has contributed to a low degree of certainty when diagnosing mycoplasmosis, especially when it is used

**Table 1** – Seroreactivity of hens vaccinated against *M. gallisepticum* determined by SAR and ELISA, according to production stage and age, in the Bastos region and Guatapar, SP (So Paulo, 2009).

Production stage (age)	SAR vaccinated		ELISA vaccinated	
	Reactive %	Non reactive %	Reactive %	Non reactive %
	(subtotal)	(subtotal)	(subtotal)	(subtotal)
<b>Beginning</b> (17-35 weeks)	80.30 (98/122)	19.70 (24/122)	81.15 (99/122)	18.85 (23/122)
<b>Middle</b> (36-53 weeks)	91 (111/122)	9 (11/122)	89.85 (124/138)	10.15 (14/138)
<b>Final</b> (> 54 weeks)	69.70 (269/310)	30.30 (41/310)	90.80 (267/294)	9.2 (27/294)
<b>Total</b>	86.3 (478/554)	13.7 (76/554)	88.40 (490/554)	11.60 (64/554)
<b>Chi-squared</b>	(P = 0.0499)		(P = 0.0162)	

**Table 2** – Seroreactivity of hens not vaccinated against *M. gallisepticum* determined by SAR, according to production stage and age, in the Bastos region (So Paulo, 2009).

Production stage (age)	SAR non-vaccinated		ELISA non-vaccinated	
	Reactive %	Non reactive %	Reactive %	Non reactive %
	(subtotal)	(subtotal)	(subtotal)	(subtotal)
<b>Beginning</b> (17-35 weeks)	50.75 (34/67)	49.25 (33/67)	92.50 (62/67)	7.50 (5/67)
<b>Middle</b> (36-53 weeks)	100.00 (48/48)	0	97.90 (47/48)	2.10 (1/48)
<b>Final</b> (> 54 weeks)	100.00 (114/114)	0	100 (114/114)	0
<b>Total</b>	85.50 (196/229)	14.50 (33/229)	97.40 (223/229)	2.60 (6/229)
<b>Chi-squared</b>	(P < 0.001)		(P < 0.001)	

**Table 3** – Comparison of GMT of vaccinated birds determined by ELISA for *M. gallisepticum*, according to production stage and age, in the Bastos region and Guatapar, SP, by Tukey test (So Paulo, 2009).

Production stage (age)	Number of lots	Mean GMT*	SD	CV minimum	CV maximum	GMT minimum	GMT maximum	Confidence interval 95%
<b>beginning</b> (17-35 weeks)	8	3,645.0a	2,736.1	25.2 %	118.1%	1,417	8,413	1,357.2 to 5,932.8
<b>middle</b> (36-53 weeks)	8	7,927.6a	5,394.6	22.1 %	63.0%	741	15,682	3,416.9 to 12,438
<b>Final</b> (>54 weeks)	20	6,810.3a	4,218.7	17.4 %	81.2%	986	19,359	4,835.9 to 8,784.7

\* Means followed by the same letter in the rows are not significantly different (P>0.05)

alone (BRASIL, 1994; MENDONÇA et al., 2003; MENDONÇA et al., 2004; BUCHALA et al., 2006; CARDOSO et al., 2006). The false-positive reactions can also be attributed to the presence of globulin and other serum components in the growth medium used in the mycoplasma culture for production of antigen for SAR test (AHMAD et al., 1988). It is also known that there are significant differences in sensitivity and specificity of SAR antigens (ROSALES, 1999) and variability among lots of the same manufacturer and between diagnosis laboratories (METTIFOGO & BUIM, 2009). However, we used antigens from the same lot and manufacturer for all SAR tests. The possibility of false-positive by contaminated serum was also (METTIFOGO & BUIM, 2009) ruled out since we used sterile new disposable syringes and needles for each bird and serology was performed as soon as the serum was separated from the blood.

The live vaccine strains ts-11 and F were used in the Bastos region, while in Guatapar only the strain ts-11 was used. On way to differentiate infection caused by field strains or by vaccine strains is to perform the multiplex PCR, which assists the differential diagnosis of isolated and epidemiological studies (METTIFOGO & BUIM, 2009), and such study can be performed in a later stage. The high levels of seroreactivity to SAR and ELISA associated with the lack of clinical symptoms suggest the occurrence of attenuated vaccine strains or field of low virulence. Only an epidemiological study isolating *M. gallisepticum* to perform molecular characterization and differentiation can determine the strains that are stimulating the humoral response of the hens.

## CONCLUSION

The high percentage of hens vaccinated with live attenuated strain of *M. gallisepticum* reactive to both ELISA and SAR simultaneously, associated with the absence of clinical symptoms indicate that there was low vaccine failure in these regions, and that vaccination stimulated the immune response and is effectively protecting the animals against chronic respiratory disease.

## ACKNOWLEDGMENTS

Thanks are due to the veterinarian Wagner Watanabe, of Associao Paulista de Avicultura, and to the technician Cristovo Altero, of EDA in Tup, for helping collecting the samples. To BIOVET, for donating the SAR antigen for *M. gallisepticum*, and to APA, for donating the kits ELISA MG.

## REFERENCES

AHMAD, I.; KLEVEN, S. H.; AVAKIAN, A. P.; GLISSON, J. R. Sensitivity and specificity of *Mycoplasma gallisepticum* agglutination antigens

prepared from medium with liposomes substituting for serum. *Avian Diseases*, v.32, n.3, p.519-526, 1988.

ALVES, S. P. **Uso da zootecnia de preciso na avaliao do bem-estar bioclimtico de aves poedeiras em diferentes sistemas de criao.** Piracicaba: Universidade de So Paulo, 2006. 128 p. Tese (Doutorado em Agronomia) - Escola Superior de Agricultura Luiz de Queiroz, 2006.

BRASIL. **Programa Nacional de Sanidade Avcola.** Atos legais. Portaria 193. Dirio Oficial da Repblica Federativa do Brasil, Poder Executivo, Braslia – DF, 19 set. 1994.

BUCHALA, F. G.; ISHIZUKA, M. M.; MATHIAS, L. A.; BERCHIERI JNIOR, A.; CASTRO, A. G. M.; CARDOSO, A. L. S. P.; TESSARI, E. N. C.; KANASHIRO, A. M. I. Deteco de resposta sorolgica contra *Mycoplasma* em aves de criatrios de “fundo de quintal” prximos a exploraoes comerciais do Estado de So Paulo. *Arquivos do Instituto Biolgico*, v.73, n.2, p.143-148, 2006.

BUTCHER, G. D. [2009]. Factors to consider in serologic testing for *Mycoplasma gallisepticum* and *Mycoplasma synoviae*. VM126 series. **Veterinary Medicine Large Animal Clinical Sciences Department, Florida, Cooperative Extension Service, Institute of Food and Agricultural Sciences, University of Florida.** April 2009. Disponvel em: <<http://edis.ifas.ufl.edu/VM126>> acesso em 01/10/2009.

CARDOSO, A. L. S. P.; TESSARI, E. N. C.; CASTRO, A. G. M., KANASHIRO, A. M. I.; STOPPA, G. F. Z. Prova de soroaglutinao rpida em galinhas reprodutoras como monitoria sorolgica de micoplasmoses. *Arquivos do Instituto Biolgico*, v.70, p.31, 2006. Suplemento 2.

COORDENADORIA DE DEFESA AGROPECURIA DO ESTADO DE SO PAULO. CDA. **Cadastro de Estabelecimentos Avcolas do Estado de So Paulo (CEASP).** Disponvel em: <<http://www.cda.sp.gov.br>> acesso em 01/10/2009.

DANELLI, M. G. M. Desempenho dos testes de soroaglutinao rpida e ELISA frente ao isolamento no diagnstico de *Mycoplasma gallisepticum* em galinhas. *Revista Brasileira de Medicina Veterinria*, v.21, n.3, p.101-104, 1999.

GARCIA, E. A.; MOLINA, A. B. Atualidades no manejo de poedeiras. In: CONGRESSO DE PRODUO, COMERCIALIZAO E CONSUMO DE OVOS, 6., 2008, Indaiatuba. *Anais...* Indaiatuba: Associao Paulista de Avicultura, 2008. p.10-21.

INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATSTICA. IBGE. **Guatapar / SP – Dados bsicos.** Disponvel em:

<<http://www.ibge.gov.br/cidadesat/painel/painel.php?codmun=351885#>> acesso em 01/10/2009.

ITO, N. M. K.; MIYAJI, C. I.; LIMA, E. A.; OKABAYASHI, S. Micoplasmoses em aves. In: CURSO BÁSICO DE SANIDADE AVÍCOLA FORT DODGE, 9., 2002, Jaguariúna. **Anais...** Jaguariúna: Fort Dodge, 2002. p.27-53.

MENDONÇA, G. A.; PÓLO, P. A.; NASCIMENTO, E. R.; LIGNON, G. B. A. Prova de SAR em galinhas poedeiras infectadas por micoplasmoses e salmonelose. In: CONFERÊNCIA APINCO DE CIÊNCIA E TECNOLOGIA AVÍCOLAS, 21., 2003, Santos. **Anais...** Santos: APINCO, 2003. p.116.

MENDONÇA, G. A.; NASCIMENTO, E. R.; LIGNON, G. B.; PÓLO, P. A. O emprego das provas de SAR e HI como rotina laboratorial para evidênciação de *Mycoplasma gallisepticum*. **Revista Brasileira de Ciência Avícola**, v.4 , p.177, 2004. Suplemento 6.

METTIFOGO, E.; BUIM, M. R. *Mycoplasma gallisepticum*. In: REVOLLEDO, L.; FERREIRA, A. J. P. (Eds.). **Patologia Aviária**. Barueri: Editora Manole Ltda., 2009. p.86-100.

MUÑOZ, R.; SAYD, S.; SHOBERG, R. **Monitoria para Mycoplasmas em avicultura**. Disponível em <[http://al.idexx.com/produccion/boletin/noticiasM.gallisepticumms\\_pg.jsp](http://al.idexx.com/produccion/boletin/noticiasM.gallisepticumms_pg.jsp)> acesso em 01/10/2009.

NASCIMENTO, E. R. Micoplasmoses aviárias. In: BERCHIERI JÚNIOR, A.; MACARI, M. (Eds.) **Doença das aves**. Campinas: Facta, 2000. p.217-224.

NOORMOHAMMADI, A. H.; BROWNING, G. F.; COWLING, P. J.; O'ROURKE, D.; WHITHEAR, K. G.; MARKHAM, P. F. Detection of antibodies to *Mycoplasma gallisepticum* vaccine ts-11 by an autologous Enzyme-Linked Immunosorbent Assay. **Avian Diseases**, v.46, n.2, p.405-411, 2002.

RAUBER, R. H.; FLÔRES, M. L.; PEREIRA, C. E.; FIORENTIN, L. Ocorrência de *Mycoplasma gallisepticum* em poedeiras comerciais no Estado do Rio Grande do Sul e sua relação com a biosseguridade. **Revista Brasileira de Ciência Avícola**, v.1, p.206, 2004. Suplemento 6.

ROSALES, A. G. Monitoria sorológica em aves. In: CONFERÊNCIA APINCO DE CIÊNCIAS E TECNOLOGIA AVÍCOLAS, 17., 1999, Campinas. **Anais...** Campinas: APINCO, 1999. v.1, p.46-52.

SANTOS, B. M.; MARÍN-GÓMEZ, S. Y.; PAULA, A. C. B. Confiabilidade de um teste de triagem para micoplasmose aviária. **Arquivo Brasileiro de Medicina Veterinária e Zootecnia**, v.1, n.1, p.18-23, 2007.

SÃO PAULO. Resolução SAA-27, de 30 de setembro de 2003. Considera a laringotraqueíte infecciosa, doença das aves, de peculiar interesse do Estado, e estabelece as exigências a serem cumpridas pelos estabelecimentos avícolas das regiões especificadas e dá outras providências. **Diário Oficial do Estado de São Paulo**, v.186, n.58, 30 set. 2003. Seção I, p. 15.

SIMAS, V. S.; PEREIRA, V. L. A.; SILVA, R. C. F.; BARRETO, M. L.; ALMEIDA, J. F.; NASCIMENTO, E. R. Soroaglutinação rápida para *Mycoplasma galissepticum*, *Mycoplasma synoviae* e *Salmonella pullorum* em poedeiras comerciais e caipiras do RJ. In: CONFERÊNCIA APINCO 2008 DE CIÊNCIA E TECNOLOGIA AVÍCOLAS, 26., 2008, Santos. **Revista Brasileira de Ciência Avícola**, v.2, p.222, 2008. Suplemento 10.